Benjamin D Greenbaum

Title: The Innovative Contributions of Benjamin D. Greenbaum

Introduction

Benjamin D. Greenbaum is a notable inventor based in New York, NY (US), recognized for his significant contributions to cancer treatment through innovative technologies. He holds one patent that showcases his expertise in the field of immunotherapy.

Latest Patents

His patent, titled "Neoantigens and uses thereof for treating cancer," presents systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen. The process involves obtaining sequencing reads from samples representative of the cancer. A human leukocyte antigen type and a plurality of clones are determined from these sequencing reads. For each clone, an initial frequency in the samples is established, and a corresponding clone fitness score is computed. This score is derived by identifying neoantigens in the respective clone, calculating a recognition potential for each neoantigen, and aggregating these potentials to determine the clone fitness score. Ultimately, a total fitness score is computed by summing the clone fitness scores across the plurality of clones, quantifying the likely responsiveness of the subject to the immunotherapy regimen.

Career Highlights

Throughout his career, Benjamin D. Greenbaum has worked with esteemed institutions, including the Icahn School of Medicine at Mount Sinai. His work has significantly advanced the understanding and treatment of cancer through innovative methodologies.

Collaborations

He has collaborated with notable colleagues, including Marta Luksza and Vinod P. Balachandran, contributing to the advancement of cancer research and treatment strategies.

Conclusion

Benjamin D. Greenbaum's innovative work in the field of cancer treatment exemplifies the impact of scientific research on healthcare. His contributions continue to pave the way for advancements in immunotherapy and cancer care.